SCHEMBL3680646

SCHEMBL3680646

C[N+](C)(C)CC(CC(=O)[O-])OS(=O)(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
CYP1A2 P05177 1/20 0.59
HRH1 P35367 1/20 0.59
CYP2C19 P33261 2/20 0.56
RECQL P46063 1/20 0.56
SLC22A16 Q86VW1 1/20 0.50
SLC25A20 O43772 3/20 0.48
TP53 P04637 2/20 0.48
CYP2D6 P10635 2/20 0.48
TSHR P16473 2/20 0.48
SLC6A5 Q9Y345 2/20 0.48
KDM4E B2RXH2 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C9 P11712 1/20 0.48
NFKB1 P19838 1/20 0.48
THPO P40225 1/20 0.48
HIF1A Q16665 1/20 0.48
HSD17B10 Q99714 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29358101 1.00 MEN1 (0.59) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL8988393 0.86 MEN1 (0.56) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL8988387 0.86 MEN1 (0.56) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL8949610 0.86 MEN1 (0.56) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL9189329 0.86 MEN1 (0.59) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL9187836 0.86 MEN1 (0.59) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL8747889 0.86 MEN1 (0.59) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL5082341 0.86 MEN1 (0.59) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL5082339 0.86 MEN1 (0.59) MEN1KMT2ACYP1A2HRH1CYP2C19
Hydrochloric Acid SCHEMBL8896646 0.84 MEN1 (0.57) MEN1KMT2ACYP1A2HRH1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066001-A1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES SILTI AG (CH) 2024-02-29 US claimed
US-20230346735-A1 Nutritional Composition Comprising Carnitine and Method for Treating or Preventing an Infection in a Mammal LONZA GREENWOOD LLC 2023-11-02 US claimed
CN-115317398-B Ionic liquid collagen preparation and preparation method and application thereof 广州樊文花化妆品有限公司 2023-09-19 CN claimed
EP-3164125-B1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES NAN GLOBAL LLC (US) 2023-09-06 EP claimed
EP-4125858-A1 NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL Lonza Consumer Health Inc. (US) 2023-02-08 EP claimed
CN-115317398-A Ionic liquid collagen preparation and preparation method and application thereof 广州樊文花化妆品有限公司 2022-11-11 CN claimed
WO-2021221741-A1 NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL LONZA CONSUMER HEALTH INC. (US) 2021-11-04 WO claimed
CN-113387836-A Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, or treating or preventing the development of diabetes NAN全球有限责任公司 2021-09-14 CN claimed
US-20210186918-A1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES MOLECULE X LLC 2021-06-24 US claimed
EP-3164125-A2 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES Nan Global, LLC (US) 2017-05-10 EP claimed
EP-1218001-B1 ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME SIGMA TAU HEALTHSCIENCE SPA (IT) 2008-12-31 EP claimed
CN-101120935-A Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same SIGMA TAU HEALTHSCIENCE SPA (IT) 2008-02-13 CN claimed
US-7303765-B2 Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) 2007-12-04 US claimed
US-20050124558-A1 Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) 2005-06-09 US claimed
EP-1218001-A4 ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME SIGMA TAU HEALTHSCIENCE SPA (IT) 2005-05-18 EP claimed
CN-1399549-A Ultra-fine L-carnitine, methods of making, compositions containing, and methods of using SIGMA TAU HEALTHSCIENCE SPA (IT) 2003-02-26 CN claimed
US-20020111383-A1 Ultrafine L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) 2002-08-15 US claimed
EP-1218001-A1 ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME Sigma-Tau Healthscience S.p.A. (IT) 2002-07-03 EP claimed
WO-2001017525-A1 ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME SIGMA-TAU HEALTHSCUIENCE S.P.A (IT) 2001-03-15 WO claimed
US-4602039-A HYDROPHOPIC;BIOLOGICAL INJECTIONS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 1986-07-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210186918-A1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES GPR119, CPT1B, CPT2 MEN1 3979/4885KMT2A 1054/4885CYP1A2 4593/4885
US-20240066001-A1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES GPR119, CPT1B, CPT2 MEN1 3979/4885KMT2A 1054/4885CYP1A2 4593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.